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This article was written is response to a request from the editor-in-chief as a result of my receiving the Governor’s Award in 
Scientific Awareness. My goal is to provide a glimpse into a 40 plus year research career that was predominately focused on 
the role of thromboxane A2 and its receptor (TP) in physiologic and pathophysiologic processes in the cardiovascular system. 
It also enumerates the lessons learned along the way that may lead to a productive research career. Those lessons were: 
perseverance; think out of the box; challenge the dogma; take risks; failure is not a bad thing; focus; select a good mentor(s); 
choose your collaborators and colleagues wisely (team science); when you start an experiment-finish it (analyze all the data); 
and take time for your family. 
 
 
This review is written in response to a request from the editor-in-
chief as a result of my receiving the Governor’s Award for 
Excellence in Scientific Awareness.  The following was adopted 
from the Keynote Address for the 50th Annual Perry V. Halushka 
MUSC Research day given on November 12, 2015.  
 The themes for my address were; lessons learned, team science 
and translational research.  These 3 themes reflect the story of my 
career in research and contributed to receiving the Governor’s 
award.   The focus of my research has been on the cardiovascular 
system and the role that thromboxane A2 plays in both 
physiologic and pathophysiologic processes.  
 
Metabolism of Arachidonic Acid 
 
In order to appreciate the role of thromboxane A2 in physiologic 
and pathophysiologic processes, one needs to have a basic 
understanding of the formation of thromboxane A2 from 
arachidonic acid.  Arachidonic acid is an essential fatty acid that 
cannot be synthesized by the mammalian species (Figure 1).  It is 
acquired from various food sources and is stored in membrane 
phospholipids and released upon activation of phospholipase A2.  
Once released it is rapidly metabolized to the labile 
endoperoxides, PGG2 and PGH2 via the enzyme fatty acid 
cyclooxygenase.  The enzyme is inhibited by aspirin and non-
steroidal anti-inflammatory drugs.  PGH2 is rapidly metabolized 
by thromboxane synthase to thromboxane A2, which is very labile 
with a t1/2 of ~30 seconds.  It is hydrolyzed to the stable but 
inactive thromboxane B2.  Thromboxane synthase is inhibited by 
imidazole and other derivatives of imidazole.  Thromboxane A2 
stimulates platelets to aggregate and vascular smooth muscle cells 
to contract. Thus, thromboxane A2 participates in hemostatic 
control of bleeding as part of a normal physiologic process.  
However, for example, in the setting of atherosclerotic 
cardiovascular disease thromboxane A2 plays a pathophysiologic 
role in vascular occlusive phenomena.  It is aspirin’s ability to 
irreversibly inhibit the platelet cyclooxygenase and thus 
thromboxane A2 that leads to its beneficial effects in the primary 
and secondary prevention of heart attacks and strokes.  
 
Endotoxemia, Thromboxane A2 and TP Receptors 
 
Around 1979, James Cook, PhD and Curtis Wise, PhD brought to 
my attention their observation that essential fatty acid deficient 
rats (EFAD) were resistant to the lethal effects of endotoxin.  
Endotoxin is the outer wall of gram negative bacteria and is 
released when the bacteria are killed.  Endotoxin causes a host 
reaction which in turn can lead to severe shock and death.  This 
situation is mostly commonly encountered when individuals have 
overwhelming bacterial infections in their blood stream.  As 
noted above, thromboxane A2 is a fatty acid derived from the 
essential fatty acid arachidonic acid (Figure 1).  
 Our hypothesis was that endotoxin stimulates the formation of 
thromboxane A2 and that it contributes to the pathophysiology of 
endotoxic shock.  We postulated that the EFAD rats could not 
make thromboxane A2 and therefore were protected from the 
lethal effects of endotoxin.   To test the hypothesis several series 
of experiments were conducted; 1) measurement of plasma levels 
of thromboxane B2 in control and endotoxin treated rats, 2) 
inhibition of the metabolism of arachidonic acid at the level of 
the cyclooxygenase using indomethacin, 3) at the level of 
thromboxane synthase using imidazole and 4) direct antagonism 
of the thromboxane (TP) receptor using 13- azaprostanoic acid.  
Endotoxin significantly increased the levels of plasma 
thromboxane B2 in the rats challenged with endotoxin compared 
to the EFAD rats and the imidazole treated rats (Figure 2) (1). 
Treatment with either indomethacin or imidazole significantly 
improved survival of the rats treated with endotoxin (Table  1) 
(1).   Ibuprofen also significantly improved the outcome of 
endotoxic shock in rats (2). Treatment of the endotoxic rats with 
13-azaprostanoic acid also significantly improved survival 
compared to the vehicle treated group (1).  Working with Dr. 
David Reines, a surgeon/intensive care physician, we 
subsequently went on to show that patients that died from 
overwhelming sepsis had a 10 fold greater level of plasma 
 
 
Figure 1. Metabolism of arachidonic acid.  Aspirin, 
indomethacin and other non-steroidal anti-inflammatory drugs 
(NSAIDS) inhibit the enzyme, fatty acid cyclooxygenase.  
Imidazole and derivatives of imidazole inhibit thromboxane 
synthase. Thromboxane A2 stimulates platelets to aggregate 




thromboxane B2 compare to those that survived a bout of sepsis 
or patients in the ICU that did not have a bout of septic shock (3).  
We also treated a group of septic patients with a thromboxane 
synthase inhibitor and showed that it was safe and effective in 
lowering plasma thromboxane B2 levels (4).  The company that 
made the thromboxane synthase inhibitor decided not to further 
develop it, so we were not able to conduct a large multicenter 
clinical trial to test its efficacy as a treatment for septic shock.  
The company along with several other companies may have 
decided to drop the development of thromboxane synthase 
inhibitors as antiplatelet agents based on the observations made 
by one of my graduate students (see below). 
 Lessons learned: Choose your collaborators and colleagues 
wisely (Team Science) (Dr. Cook and I have shared an RO1 for 
33 years.) and think out of the box. 
 
Platelet Thromboxane Formation and Platelet Aggregation 
 
Dr. John Colwell, a diabetologist at MUSC, found that diabetic 
patients’ platelets were more sensitive to aggregating agents 
compared to the appropriate controls (5). Given the role of 
thromboxane A2 in promoting platelet aggregation, we 
collaborated to determine the formation of thromboxane A2 by 
platelets from diabetic and control subjects.  We found that 
diabetic patients’ platelets made significantly more thromboxane 
A2 and at a significantly greater rate compared to the control 
subjects’ platelets (6).  In collaboration with Ron Mayfield, also a 
diabetologist, we found that improving glucose control in the 
diabetic patients decreased the formation of thromboxane A2 by 
their platelets (7). 
 In the late 70s there was a reigning hypothesis that platelet 
thromboxane A2 synthesis was a major contributor to platelet 
aggregation and that inhibition of its synthesis would confer 
significant inhibition of platelet aggregation. Along with a couple 
of my colleagues, we decided to synthesize a series of 
thromboxane synthase inhibitors as potential drugs to act as 
inhibitors of platelet aggregation.  7-IHA was one of those 
compounds.  We asked Linda Grimm a graduate student at the 
time to test its antiplatelet effects and its ability to inhibit 
thromboxane A2 synthesis. Soon after she finished the first 
experiment assessing arachidonic acid induced platelet 
aggregation, she came to my office and concluded that 7-IHA did 
not inhibit thromboxane A2 synthesis because it did not inhibit 
arachidonic acid induced platelet aggregation. I asked her if she 
had measured thromboxane B2.  She said that she had not.  So I 
told her to come back to me once she had measured thromboxane 
B2. Much to her amazement, 7-IHA significantly inhibited 
thromboxane synthesis, yet did not inhibit platelet aggregation. 
Her results completely disproved the reigning hypothesis.  The 
saga continues because, when we submitted the paper for 
publication, the review came back with a rejection and my take 
on the review was that it was pejorative and written by the person 
who was promulgating the hypothesis.  I appealed to the editor 
and he agreed to have the manuscript reviewed by different 
reviewers. Within about 2 weeks, the manuscript came back 
accepted as is (8).   
 Lessons learned: When you start an experiment, finish it with a 
complete analysis of the data, challenge the dogma and 
perseverance.  
 
“When you come to a fork in the road, take it”, Yogi Berra 
 
We had conducted many studies demonstrating a role for 
thromboxane A2 in physiologic and pathophysiologic processes 
and decided that it was time to start to characterize the binding 
characteristics of thromboxane A2 (TP) receptors and their 
signaling mechanisms.  However, there were no radioactive 
ligands available that could be used for characterization of the 
binding characteristics and regulation of their expression. So 
along with our chemistry colleagues, we synthesized a compound 
13-cisAPO, a derivative of 13-azaprostanoic acid, that could be 
radiolabelled with 125I using a simple one-step process.  With the 
compound in hand, we took a 1 year sabbatical in London, 
England to work with Dr. John MacDermot, to begin to 
characterize the binding characteristics of the TP receptor using 
125Iodo-cisAPO. Little did we know that we would run into many 
challenges, the most critical one was that 125Iodo-cisAPO had a 
very low affinity for the receptor, making it very difficult to get 
specific binding to the platelet TP receptor.  Nonetheless, with 
John MacDermot’s guidance, we persevered and were able to 
ultimately demonstrate specific binding (9) and establish the 
concept of making 125I labeled ligands for the characterization of 
TP receptors (10-12). 
 Lessons learned:  Think out of the box, Choose your 
collaborators and colleagues wisely, Failure is not a bad thing, 
Take risks, Focus and Perseverance. 
 
Characterization of the TP Receptors 
 
With a generous gift of a chemical precursor from the ONO 
pharmaceutical company, Dale Mais, a postdoctoral fellow, and 
ultimately assistant professor, synthesized a series of 
thromboxane receptor antagonists.  Using these compounds, we 
characterized the TP receptor in platelets and blood vessels and 
demonstrated that they represented two distinct classes of 
 
Figure 2.  Plasma levels of thromboxane B2 following a 
bolus injection of endotoxin in rats.  The levels of 
thromboxane B2 were significantly (p<0.01) greater in 
the control rats compared to those treated with 
indomethacin or imidazole. N=8 to 10/group. Modified 
from J. Clinical Investigation 65:227, 1981, J. Cook et 
al. 
 
Table 1.  Survival rates after a lethal injection of endotoxin in rats. 
 Time after endotoxin (hrs) 
Group (Dead/Total) 5 12 24 48 
Control 14/20 19/20 19/20 19/20 
EFAD (7-8 wk old) 0/12 1/12 7/12 8/12 
EFAD (12-13 wk old) 0/14 0/14 0/14 0/14 
Indomethacin I.V. 0/8 0/8 1/8 1/8 




receptors (13-15).  The receptor was cloned by Narumyia et al, 
and since they could not find a second transcript, they concluded 
that there was only one class of receptors (16).  However, a splice 
variant was subsequently discovered (17) and we also generated 
additional data to support the notion that there were two classes 
of receptors (18, 19).  
 Lessons learned: Believe in your data based on first principles. 
 
 The final vignette deals with the earlier observations that some 
young male athletes abusing anabolic steroids were suffering 
strokes and heart attacks in their 20s (20) and that male rat aortas 
were more sensitive to rabbit aorta contracting substance (21), 
subsequently shown to be thromboxane A2, and that in laboratory 
animals, testosterone pretreatment enhanced thrombogenic 
stimuli (22).  We hypothesized that testosterone may increase the 
expression of TP receptors and in turn is responsible in part for 
these observations. This hypothesis was tested in cultured 
vascular smooth cells, HEL cells (model for megakaryocytes), 
rats and ultimately in normal male volunteers and patients with 
prostate cancer. Collectively, these studies demonstrated that in 
both pharmacologic doses as well as endogenous levels, 
testosterone may regulate the expression of TP receptors (23-26). 
 Throughout my research career, I have learned many lessons 
that help to make one more successful. They are enumerated 
below. 
 
Dr. H’s “TOP 10” lessons for success 
 Perseverance 
 Think out of the box 
 Challenge the dogma 
 Take risks 
 Failure is not a bad thing 
 Focus 
 Select a good mentor(s) 
 Choose your collaborators and colleagues wisely (team 
science) 
 When you start an experiment-finish it (analyze all the data) 




The research that I have conducted over the 40 plus years would 
not have been possible without the devotion, hard work and 
intellectual contribution of my 27 trainees and 17 colleagues.  To 
them, I owe a sincere debt of gratitude.  I also want to 
acknowledge the grant support that I received early in my career 
from the Pharmaceutical Research and Manufacturers Foundation 
and the Burroughs Wellcome Scholar Award in Clinical 
Pharmacology, those grants were instrumental in supporting the 
early stages of my career.  The major portion of my research was 
funded from the NIH, American Heart Association and 
pharmaceutical companies.  
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